Premium
Antimetastatic effects of Eclipta prostrata extract on oral cancer cells
Author(s) -
Liao MiaoYu,
Chuang ChunYi,
Hsieh MingJu,
Chou YingErh,
Lin ChiaoWen,
Chen WenRong,
Lai ChihTing,
Chen MuKuan,
Yang ShunFa
Publication year - 2018
Publication title -
environmental toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 77
eISSN - 1522-7278
pISSN - 1520-4081
DOI - 10.1002/tox.22577
Subject(s) - metastasis , cancer , western blot , kinase , cancer cell , matrix metalloproteinase , cancer research , mapk/erk pathway , p38 mitogen activated protein kinases , traditional medicine , protein kinase a , chemistry , pharmacology , biology , medicine , biochemistry , gene
Eclipta prostrata , a traditional Chinese medication, has been used for the treatment of several diseases. However, the molecular mechanism underlying the effects of Eclipta prostrata extracts (EPE) on human oral cancer cell metastasis remains unclear. We thus examined the effects of EPE on metastasis promoting proteins in oral cancer. Our results revealed that the EPE attenuated SCC‐9, HSC‐3, and TW2.6 cell migration and invasiveness by reducing matrix metalloproteinase (MMP)‐2 enzyme activities. In addition, Western blot analysis revealed that EPE significantly reduced the levels of phosphorylated extracellular signal‐regulated kinase 1/2 (ERK 1/2) but not those of c‐Jun N‐terminal kinase (JNK) 1/2 and p38. In conclusion, we found that EPE could inhibit oral cancer metastasis through the inhibition of MMP‐2 expression. Therefore, EPE may be used to prevent the metastasis of oral cancer, and has the potential to be applied to cancer treatment.